溢价收购亚太药业控制权，新实控人看好公司长期发展前景

Core Viewpoint - The control of Zhejiang Apac Pharmaceutical Co., Ltd. has officially changed hands to Mr. Qiu Zhongxun, indicating a strategic shift in the company's direction and potential for growth in the pharmaceutical industry [1][2]. Group 1: Control Change and Valuation - The current controlling shareholder, Ningbo Fubang Holding Group, will transfer a total of 108,945,566 shares (14.61% of total equity) to Zhejiang Xinghao Holding Partnership and its affiliates [2]. - The new controlling party has valued Apac Pharmaceutical at over 6 billion yuan, representing a nearly 50% premium compared to the market valuation of approximately 4.2 billion yuan prior to the suspension of trading [2]. Group 2: Innovation and Product Development - Apac Pharmaceutical is focusing on a dual strategy of "chronic disease management + precision medicine," with ongoing projects such as CX3002 (an oral hypoglycemic drug) and a sustained-release patch for pain relief [3]. - The company's stock has seen a significant increase, with a rise of over 135% this year, reflecting investor confidence in the pharmaceutical sector's shift towards innovation [3]. Group 3: Future Strategy and Leadership - Under the new leadership of Mr. Qiu Zhongxun, the company aims to enhance operational efficiency in traditional generic drug business while increasing investment in innovative drug research and development [4]. - Mr. Qiu's extensive industry background and resources from his role in the digital pharmaceutical platform "Yao Dou Technology" are expected to provide unique advantages for Apac Pharmaceutical's growth and commercialization of innovative products [4].